Genmab — Juni 2020

Solsen

JW nævner også at de forventer at indsende ansøgning om godkendelse i første indikation for epco i 2022.

Solsen

Det er hurtigt !

E_L

@Solsen it was written exactly like that in the press release " For the discovery research partnership, Genmab will conduct Phase 1 studies for these programs. AbbVie retains the right to opt-in to program development."

GeorgeBest

@kkjoel 11:42 Ikke nogen opdatering på Bloomberg kursmål det senste år, kan ikke gå længere tilbage

E_L

Bryan Garnier höjer riktkursen för Genmab till 2 000 danska kronor (1 950), upprepar neutral - BN (Finwire)

Sukkeralf

E L - and there is a opt in payment thats not included in the 2 billion milestones

E_L

are
you sure it is not included?

Solsen

Yes but the question yesterday was - is
these programs in clinical developement alredy. NO

Sukkeralf

E L - pretty sure Jan said that. But it could be a small amount

E_L

ok

E_L

Genmab/Citi: Abbvie-aftale er bedre end ventet https://npinvestor.dk/nyheder/genmabciti-abbvie-aftale-er-bedre-end-ventet

E_L

H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Genmab to $40 from $34 and keeps a Buy rating on the shares. The analyst views AbbVie as a "solid partner" for Genmab alongside Janssen

The Fly | LANDINGPAGENEWS.PHP

Real-time market news, financial data, stock research, and portfolio tools from The Fly.

(thefly.com)

GeorgeBest

GENMAB A/S GMAB.O: SUNTRUST ROBINSON RAISES TARGET PRICE TO $39 FROM $36 - Reuters News

bikube

MedWatch påstår, at Guggenheims nye kursmål på 2350 er det hidtil højeste. Har vi ikke set mål på 2500?

GeorgeBest

Jo UBS og Citi har 2500

kkjoel

Og nu osse H.C. Wainright ($40 ~ 2620 (kurs 6,55)) samt Suntrust Robinson ($39 ~ 2555).

kkjoel

Jeg har noteret 30 finanshusmål med snit på 1931.

E_L

Abbvie at GS conference from minute 29 https://kvgo.com/GSHC/AbbVie-june-2020

GeorgeBest

thanks E L

E_L

and Seattle Genetics from minute 13:50 for TV
https://kvgo.com/GSHC/seattle-genetics-june-2020